ALKERMES PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.68 USD | +0.98% |
|
+3.48% | -11.03% |
| Apr. 09 | Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday | MT |
| Apr. 09 | Alkermes Says Potential Narcolepsy Drug Improves Wakefulness in Phase 1b Study | MT |
Presentation Operator MessageOperator (Operator)Greetings. Welcome to the Alkermes Fourth Quar...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Calendar
2024-05-01
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
24.68
USD
Average target price
35.25
USD
Spread / Average Target
+42.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.03% | 4.18B | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ALKS Stock
- News Alkermes plc
- Transcript : Alkermes plc, Q4 2023 Earnings Call, Feb 15, 2024
